Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. 2006N-0105]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Fax written comments on the collection of information by October 23, 2006.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn:  FDA Desk Officer, FAX:  202-395-6974.
 FOR FURTHER INFORMATION CONTACT: Liz Berbakos, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD  20857, 301-827-1482.


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Environmental Impact Considerations—(OMB Control Number 0910-0322)—Extension FDA is requesting OMB approval for the reporting requirements contained in the FDA regulation “Environmental Impact Considerations.” The National Environmental Policy Act (NEPA) (42 U.S.C. 4321-4347), states national environmental objectives and imposes upon each Federal agency the duty to consider the environmental effects of its actions. Section 102(2)(C) of NEPA requires the preparation of an environmental impact statement (EIS) for every major Federal action that will significantly affect the quality of the human environment. The FDA NEPA regulations are in  part 25 (21 CFR part 25). All applications or petitions requesting agency action require the submission of a claim for a categorical exclusion or an environmental assessment (EA). A categorical exclusion applies to certain classes of FDA-regulated actions that usually have little or no potential to cause significant environmental effects and are excluded from the requirements to prepare an EA or EIS. Section 25.15(a) and (d) specifies the procedures for submitting to FDA a claim for a categorical exclusion. Extraordinary circumstances (§ 25.21), which may result in significant environmental impacts, may exist for some actions that are usually categorically excluded. An EA provides information that is used to determine whether an FDA action could result in a significant environmental impact. Section 25.40(a) and (c) specifies the content requirements for EAs for nonexcluded actions. This collection of information is used by FDA to assess the environmental impact of agency actions and to ensure that the public is informed of environmental analyses. Firms wishing to manufacture and market substances regulated under statutes for which FDA is responsible must, in most instances, submit applications requesting approval. Environmental information must be included in such applications for the purpose of determining whether the proposed action may have a significant impact on the environment. Where significant adverse effects cannot be avoided, the agency uses the submitted information as the basis for preparing and circulating to the public 
                    ( print page 55485)
                    an EIS, made available through a 
                    **Federal Register**
                     document also filed for comment at the Environmental Protection Agency (EPA). The final EIS, including the comments received, is reviewed by the agency to weigh environmental costs and benefits in determining whether to pursue the proposed action or some alternative that would reduce expected environmental impact. Any final EIS would contain additional information gathered by the agency after the publication of the draft EIS, a copy of or a summary of the comments received on the draft EIS, and the agency's responses to the comments, including any revisions resulting from the comments or other information. When the agency finds that no significant environmental effects are expected, the agency prepares a finding of no significant impact (FONSI). In the 
                    **Federal Register**
                     of March 29, 2006 (71 FR 15753), FDA published a 60-day notice requesting public comment on the information collection provisions to which FDA received one comment. The comment said it supports the current FDA approach to assessing potential environmental impact under NEPA.  However, the comment questioned whether one aspect of the collection of information is necessary for the proper performance of FDA's functions, including whether the information has practical utility, and contended that eliminating the collection of information would minimize the burden on respondents. Specifically, the comment suggested that FDA should “eliminate unnecessary work” related to requests for categorical exclusions for actions on certain investigational new drug applications (INDs).  Section 25.31 lists classes of actions that are categorically excluded and, therefore, ordinarily do not require the preparation of an EA or an EIS.  Section 25.31(e) lists an “action on an IND” as one of these classes of actions.  The comment proposed that § 25.31(e) be amended as follows:   “Action on INDs where the drug or biologic product is derived from wild plants or animals.  Action on other types of INDs do not require a claim for a categorical exclusion.”  The comment proposed that categorical exclusions should be automatically granted for actions on INDs where the drug or biologic products are not derived from wild plants or animals. The comment proposed this amendment to § 25.31(e) for the following reasons, each of which suggests that claims for categorical exclusion for action on an IND have little practical utility and amending § 25.31(e) as proposed represents a way to minimize the burden of the collection of information: 1.   FDA's guidance document entitled “Environmental Assessment of Human Drug and Biologics Applications” (July 1998) states:  “INDs generally involve relatively small quantities of a drug or biologic product and treatment of a limited number of patients.  Many INDs never result in the filing of an NDA or application for marketing approval of a biologic product, which would allow for the wide-spread commercial sale of the product.  CDER and CBER  will evaluate INDs on a case-by-case basis where the drug or biologic product is derived from wild plants or animals to determine whether the extraordinary circumstance provision in  § 25.21 is invoked.” (See section III.C.3.b.ii of the guidance document). 2.    Pharmaceutical companies have been providing claims for categorical exclusion for action on an IND since the early 1990's for active pharmaceutical ingredients (APIs) in all therapeutic classes, and the companies have no indication that FDA has used these claims as the basis for denials pertinent to potential environmental impact as described under NEPA. 3.   Usage of an API under an IND is “site limited and time bounded,” indicating that “the potential for patient excretion of an API to the environment is extremely limited.” 4.    The potential risk from pharmaceuticals in the environment pertains to long-term, chronic exposure, and usage of an API under an IND will not result in the type of exposure widely accepted as being of potential environmental concern.  The comment also stated that prior to marketing approval of an API, FDA will have the opportunity to review potential environmental impact through its EA requirements. 5.    The comment concluded that amending § 25.31(e) as proposed would have “eliminated work on up to 1933 categorical exclusions (15,464 hours) for INDs in 2005 that ultimately had no practical utility.” FDA appreciates the comment requesting that § 25.31(e) be amended so that categorical exclusions could be automatically granted for actions on INDs where the drug or biologic products are not derived from wild plants or animals.  The purpose of the March 29, 2006, 
                    **Federal Register**
                     notice and this notice, however, is to afford an opportunity for comment on the information collection requirements and burden estimates for part 25, and to request that OMB extend approval for that collection.  Because the comment requests a rulemaking change, we have forwarded it to the office in each center that is responsible for the information collection requirements in part 25 so that the comment may be considered for any future amendments to the regulations. FDA estimates the burden of this collection of information as follows: Estimated Annual Reporting Burden for Human Drugs Under 21 CFR 312.23(a)(7)(iv)(e), 314.50(d)(1)(iii), and 314.94(a)(9)(i), each  IND, new drug application (NDA), and abbreviated new drug application (ANDA) must contain a claim for categorical exclusion under § 25.30 or § 25.31 or an EA under § 25.40. In 2005, FDA received 1,933 INDs from 1,517 sponsors, 114 NDAs from 94 applicants, 2,682 supplements to NDAs from 293 applicants, 777 ANDAs from 161 applicants, and 4,318 supplements to ANDAs from 219 applicants. FDA estimates that it receives approximately 9,813 claims for categorical exclusions as required under § 25.15(a) and (d), and 11 EAs as required under § 25.40(a) and (c). Based on information provided by the pharmaceutical industry, FDA estimates that it takes sponsors or applicants approximately 8 hours to prepare a claim for a categorical exclusion and approximately 3,400 hours to prepare an EA. **Table 1.—Estimated Annual Reporting Burden for Human Drugs1**
21 CFR Section
No. of Respondents
Annual Frequency per Response
Total Annual Responses
Hours per Respondent
Total Hours25.15(a) and (d)
2,284
4.32
9,813
8
78,50425.40(a) and (c)
11
1
11
3,400
37,400Total




115,9041
                        There are no capital costs or operating and maintenance costs associated with this collection of information.
 
 
 Estimated Annual Reporting Burden for Human Foods Under 21 CFR 71.1, 171.1, 170.39, and 170.100, food additive petitions, color additive petitions, requests for exemption from regulation as a food additive, and submission of a food contact notification (FCN) for a food contact substance must contain either a claim of categorical exclusion under § 25.30 or § 25.32, or an EA under § 25.40. From 2003 to 2005, FDA received an annual average of 88 industry submissions. FDA estimates that it received an annual average of 57 claims of categorical exclusions as required under § 25.15(a) and (d), and 31 EAs as required under § 25.40(a) and (c). FDA estimates that, on average, it takes petitioners, notifiers, or requestors approximately 3 hours to prepare a claim of categorical exclusion and approximately 210 hours to prepare an EA. **Table 2.—Estimated Annual Reporting Burden for Human Foods1**
21 CFR Section
No. of Respondents
Annual Frequency per Response
Total Annual Responses
Hours per Respondent
Total Hours25.15(a) and (d)
57
1.4
80
3
24025.40(a) and (c)
31
1.3
39
210
8,190Total




8,4301
                        There are no capital costs or operating and maintenance costs associated with this collection of information.
 Estimated Annual Reporting Burden for Medical Devices Under 21 CFR 814.20(b)(11), premarket approvals (original premarket approval applications (PMAs) and supplements) must contain a claim for categorical exclusion under § 25.30 or § 25.34 or an EA under § 25.40. In 2005, FDA received 282 claims (original PMAs and supplements) for categorical exclusions as required under § 25.15(a) and (d), and 0 EAs as required under § 25.40(a) and (c). Based on information provided by less than 10 sponsors, FDA estimates that it takes approximately less than 1 hour to prepare a claim for a categorical exclusion and an unknown number of hours to prepare an EA. **Table 3.—Estimated Annual Reporting Burden for Medical Devices1**
21 CFR Section
No. of Respondents
Annual Frequency per Response
Total Annual Responses
Hours per Respondent
Total Hours25.15(a) and (d)
47
6
282
1
28225.40(a) and (c)
0
0
0
0
0Total




2821
                        There are no capital costs or operating and maintenance costs associated with this collection of information.
 Estimated Annual Reporting Burden for Biological Products Under 21 CFR 312.23(a)(7)(iv)(e) and 601.2(a), IND and biologics license applications (BLAs) must contain a claim for categorical exclusion under § 25.30 or § 25.31 or an EA under § 25.40. In 2005, FDA received 565 INDs from 426 sponsors, 27 BLAs from 12 applicants, and 737 BLA supplements to license applications from 205 applicants. FDA estimates that approximately 10 percent of these supplements would be submitted with a claim for categorical exclusion or an EA. FDA estimates that it received approximately 666 claims for categorical exclusion as required under  § 25.15(a) and (d), and 2 EAs as required under § 25.40(a) and (c). Based on information provided by industry, FDA estimates that it takes sponsors and applicants approximately 8 hours to prepare a claim for categorical exclusion and approximately 3,400 hours to prepare an EA for a biological product. **Table 4.—Estimated Annual Reporting Burden for Biological Products1**
21 CFR Section
No. of Respondents
Annual Frequency per Response
Total Annual Responses
Hours per Respondent
Total Hours25.15(a) and (d)
459
1.45
666
8
5,32825.40(a) and (c)
2
1
2
3,400
6,800Total




12,1281
                        There are no capital costs or operating and maintenance costs associated with this collection of information.
 Estimated Annual Reporting Burden for Animal Drugs Under 21 CFR 514.1(b)(14), NADAs and ANADAs, § 514.8(a)(1) supplemental NADAs and ANADAs, § 511.1 (b)(10) investigational new animal drug applications (INADs), § 570.35 (c)(1)(viii) generally recognized as safe (GRAS) affirmation petitions, and § 571.1(c) food additive petitions must contain a claim for categorical exclusion under § 25.30 or § 25.33 or an EA under § 25.40. In 2005, the Center for Veterinary Medicine (CVM) has received approximately 421 claims for categorical exclusion as required under § 25.15(a) and (d), and 14 EAs as required under § 25.40(a) and (c). Based on information provided by industry, FDA estimates that it takes sponsors/applicants approximately 8 hours to prepare a claim for a categorical exclusion and an average of 2,160 hours to prepare an EA.
                    ( print page 55487) **Table 5.—Estimated Annual Reporting Burden for Animal Drugs1**
21 CFR Section
No. of Respondents
Annual Frequency per Response
Total Annual Responses
Hours per Respondent
Total Hours25.15(a) and (d)
134
3.9
421
8
3,36825.40(a) and (c)
12
1.6
14
2,160
30,240Total




33,6081
                        There are no capital costs or operating and maintenance costs associated with this collection of information.
 Based on information provided by industry, FDA estimates that the combined annual total burden hours for all centers is 170,352. Dated: September 15, 2006. Jeffrey Shuren, Assistant Commissioner for Policy.


[FR Doc. 06-8025 Filed 9-21-06; 8:45 am] BILLING CODE 4160-01-S